SEC Form 4 · accession 0000919574-16-012965
Asterias Biotherapeutics, Inc. · AST
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Period of report
May 13, 2016
Accepted (ET)
May 13, 2016 · 5:33 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001572552
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Series A Common StockF1,F2 | May 13, 2016 | P$0 | 2,058,823 | — | A | 3,699,848 | D | |
| Series A Common StockF1,F3 | May 13, 2016 | P$0 | 0 | — | A | 3,699,848 | I | Footnote |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Warrant to Purchase Series A Common StockF1,F2,F4 | $4.37 | May 13, 2016 | P | 1,029,412 | A | — | May 13, 2021 | Series A Common Stock | 1,029,412 | 1,029,412 | D |
| Warrant to Purchase Series A Common StockF1,F3,F4 | $4.37 | May 13, 2016 | P | 0 | A | — | May 13, 2021 | Series A Common Stock | 0 | 1,029,412 | I |
| Warrant to Purchase Series A Common StockF2,F5 | $5.00 | holding | — | — | — | — | Sep 30, 2016 | Series A Common Stock | 328,205 | 328,205 | D |
| Warrant to Purchase Series A Common StockF3,F5 | $5.00 | holding | — | — | — | — | Sep 30, 2016 | Series A Common Stock | 0 | 328,205 | I |
Explanation of responses
- F1A portion of the reported securities are included within 2,058,823 AST Units purchased by Broadwood Partners, L.P. for $3.40 per AST Unit. Each AST Unit consists of one share of Series A common stock and a half warrant for a total of 2,058,823 common shares and 1,029,412 warrants to purchase 1,029,412 common shares.
- F2These securities are owned by Broadwood Partners, L.P., which is a Reporting Person.
- F3The reported securities are directly owned by Broadwood Partners, L.P. and may be deemed beneficially owned by Broadwood Capital, Inc. as General Partner of Broadwood Partners, L.P. and Neal C. Bradsher as President of Broadwood Capital, Inc. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
- F4These warrants are currently exercisable with the underlying common shares issuable 61 days following the delivery of notice of exercise to the Issuer.
- F5These warrants are currently exercisable.
Remarks
Richard LeBuhn, Senior Vice President of Broadwood Capital Inc., is a Director of the Issuer